<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503292</url>
  </required_header>
  <id_info>
    <org_study_id>17-011283</org_study_id>
    <nct_id>NCT03503292</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics and Post-Operative Nausea and Vomiting</brief_title>
  <official_title>Using Pharmacogenomics (PGx) Results to Guide Post-operative Nausea and Vomiting (PONV) Treatment Practices: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic&#xD;
      data to guide post-operative nausea and vomiting treatment in the bariatric surgical&#xD;
      population. The hypothesis is that using genotypic variation in CYP2D6 to select the&#xD;
      appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in&#xD;
      the bariatric surgical population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Episodes of Postoperative Nausea</measure>
    <time_frame>0-48 hours post bariatric surgery</time_frame>
    <description>The total number count of post operative nausea episodes were determined by nursing documentation or by treatment with rescue antinausea medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Episodes of Postoperative Vomiting</measure>
    <time_frame>0-48 hours post bariatric surgery</time_frame>
    <description>The total number count of post operative vomiting episodes were determined by nursing documentation or by treatment with rescue antinausea medication.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Postoperative Nausea</condition>
  <arm_group>
    <arm_group_label>CYP2D6 rapid metabolizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2D6 normal metabolizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
    <description>Rapid metabolizer will receive 1mg IV Granisetron</description>
    <arm_group_label>CYP2D6 rapid metabolizer</arm_group_label>
    <other_name>Kytril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Poor or normal metabolizers will receive 4mg Ondansetron IV</description>
    <arm_group_label>CYP2D6 normal metabolizer</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  A Mayo Clinic patient scheduled to undergo any bariatric surgical procedure, including&#xD;
             Roux-en-Y gastric bypass, sleeve gastrectomy, or duodenal switch.&#xD;
&#xD;
          -  Patient age 18 or above.&#xD;
&#xD;
          -  Patients must understand and provide written informed consent and HIPAA authorization&#xD;
             prior to initiation of any study-specific procedures.&#xD;
&#xD;
          -  Patient is willing to engage in a medication adjustment as part of their clinical&#xD;
             visit (when needed).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patient with uncontrolled concurrent illness including psychiatric illness, or&#xD;
             situations that would limit compliance with the study requirements or the ability to&#xD;
             willingly give written informed consent.&#xD;
&#xD;
          -  Patients that deny access to their medical records for research purposes will not be&#xD;
             included in this study. Also any patient who will be unable to have genetic testing at&#xD;
             minimum of 1 week prior to scheduled surgery or with allergies to ondansetron or&#xD;
             granisetron.&#xD;
&#xD;
          -  Any patient with prior genetic testing that is readily available in the medical record&#xD;
             will be excluded from this study.&#xD;
&#xD;
          -  Any patient that is pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvette N Martin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <results_first_submitted>October 4, 2020</results_first_submitted>
  <results_first_submitted_qc>October 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2020</results_first_posted>
  <last_update_submitted>October 4, 2020</last_update_submitted>
  <last_update_submitted_qc>October 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Yvette N. Martin, MD-PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pharmacogenetics</keyword>
  <keyword>CYP2D6</keyword>
  <keyword>Ondansetron</keyword>
  <keyword>Granisetron</keyword>
  <keyword>Bariatric surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT03503292/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CYP2D6 Rapid Metabolizer (Granisetron)</title>
          <description>Participants with CYP2D6 rapid metabolizer status received granisetron for for post operative nausea and vomiting prophylaxis and treatment&#xD;
Granisetron: Rapid metabolizer received 1mg IV Granisetron</description>
        </group>
        <group group_id="P2">
          <title>CYP2D6 Normal Metabolizer (Ondansetron)</title>
          <description>Participants with CYP2D6 poor or normal metabolizer status received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment&#xD;
Ondansetron: Poor or normal metabolizers received 4mg Ondansetron IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CYP2D6 Rapid Metabolizer (Granisetron)</title>
          <description>Participants with CYP2D6 rapid metabolizer status received granisetron for for post operative nausea and vomiting prophylaxis and treatment&#xD;
Granisetron: Rapid metabolizer received 1mg IV Granisetron</description>
        </group>
        <group group_id="B2">
          <title>CYP2D6 Normal Metabolizer (Ondansetron)</title>
          <description>Participants with CYP2D6 poor or normal metabolizer status received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment&#xD;
Ondansetron: Poor or normal metabolizers received 4mg Ondansetron IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="21.2"/>
                    <measurement group_id="B2" value="47.1" spread="13.0"/>
                    <measurement group_id="B3" value="47.2" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" spread="15.9"/>
                    <measurement group_id="B2" value="45.4" spread="9.0"/>
                    <measurement group_id="B3" value="45.4" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Episodes of Postoperative Nausea</title>
        <description>The total number count of post operative nausea episodes were determined by nursing documentation or by treatment with rescue antinausea medication.</description>
        <time_frame>0-48 hours post bariatric surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CYP2D6 Rapid Metabolizer (Granisetron)</title>
            <description>Participants with CYP2D6 rapid metabolizer status received granisetron for for post operative nausea and vomiting prophylaxis and treatment&#xD;
Granisetron: Rapid metabolizer received 1mg IV Granisetron</description>
          </group>
          <group group_id="O2">
            <title>CYP2D6 Normal Metabolizer (Ondansetron)</title>
            <description>Participants with CYP2D6 poor or normal metabolizer status received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment&#xD;
Ondansetron: Poor or normal metabolizers received 4mg Ondansetron IV</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Postoperative Nausea</title>
          <description>The total number count of post operative nausea episodes were determined by nursing documentation or by treatment with rescue antinausea medication.</description>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Episodes of Postoperative Vomiting</title>
        <description>The total number count of post operative vomiting episodes were determined by nursing documentation or by treatment with rescue antinausea medication.</description>
        <time_frame>0-48 hours post bariatric surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CYP2D6 Rapid Metabolizer (Granisetron)</title>
            <description>Participants with CYP2D6 rapid metabolizer status received granisetron for for post operative nausea and vomiting prophylaxis and treatment&#xD;
Granisetron: Rapid metabolizer received 1mg IV Granisetron</description>
          </group>
          <group group_id="O2">
            <title>CYP2D6 Normal Metabolizer (Ondansetron)</title>
            <description>Participants with CYP2D6 poor or normal metabolizer status received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment&#xD;
Ondansetron: Poor or normal metabolizers received 4mg Ondansetron IV</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Postoperative Vomiting</title>
          <description>The total number count of post operative vomiting episodes were determined by nursing documentation or by treatment with rescue antinausea medication.</description>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collect from baseline (surgery) to one week post surgery, for approximately one week.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CYP2D6 Rapid Metabolizer (Granisetron)</title>
          <description>Participants with CYP2D6 rapid metabolizer status received granisetron for for post operative nausea and vomiting prophylaxis and treatment&#xD;
Granisetron: Rapid metabolizer received 1mg IV Granisetron</description>
        </group>
        <group group_id="E2">
          <title>CYP2D6 Normal Metabolizer (Ondansetron)</title>
          <description>Participants with CYP2D6 poor or normal metabolizer status received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment&#xD;
Ondansetron: Poor or normal metabolizers received 4mg Ondansetron IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yvette N. Martin McGrew, M.D., Ph.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-7481</phone>
      <email>martin.yvette@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

